Target- |
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.AU |
First Approval Date04 Dec 2017 |
Intravenous Ferric Derisomaltose For Moderate to Severe Anemia Due To Uterine Bleeding In The Emergency Department: A Randomized Trial
The primary aim of this randomized trial is to assess the efficacy of IV Ferric Derisomaltose vs Oral Iron in the management of women with severe Iron Deficiency Anemia due to Uterine Bleeding in the emergency department.
100 Clinical Results associated with Pharmacosmos Therapeutics Inc.
0 Patents (Medical) associated with Pharmacosmos Therapeutics Inc.
100 Deals associated with Pharmacosmos Therapeutics Inc.
100 Translational Medicine associated with Pharmacosmos Therapeutics Inc.